SHAREHOLDER ALERT: WeissLaw LLP Reminds AKER, CBMG, HLIX, and MCAC Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 3, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Akers Biosciences, Inc. AKER

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. AKER in connection with the company's proposed merger with privately-held MyMD Pharmaceuticals, Inc. ("MyMD").  Under the terms of the merger agreement, AKER and MyMD will combine resulting in current MyMD stockholders owning 80% of the combined post-close company, leaving AKER stockholders with a mere 20% of the new entity.  If you own AKER shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/aker/ 

Cellular Biomedicine Group, Inc. CBMG

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. CBMG in connection with the proposed interested-party acquisition of the company by an entity consisting of CBMG's CEO Tony Liu, members of the company's management, and a consortium of investors.  Under the terms of the agreement, shareholders will receive $19.75 in cash for each share of CBMG common stock that they own.  If you own CBMG shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/cellular-biomedicine-group-inc/

Helix Technologies, Inc. HLIX

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Helix Technologies, Inc. HLIX in connection with the proposed stock-for-stock merger of the company with Medical Outcomes Research Analytics, LLC.  Under the terms of the agreement, HLIX stockholders will receive 0.02731 shares of a newly formed company, Forian Inc.  If you own HLIX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/hlix/

Mountain Crest Acquisition Corp. MCAC

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Mountain Crest Acquisition Corp. MCAC in connection with the company's proposed merger with privately-held Playboy Enterprises, Inc. ("Playboy").  Under the terms of the agreement, MCAC will acquire Playboy through a reverse merger that will result in Playboy becoming a publicly-traded company.  The deal has an enterprise value of approximately $415 million.  If you own MCAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/mcac/

SOURCE WeissLaw LLP